Market Overview

Oppenheimer Maintains Outperform Rating on Mindray Medical


According to Oppenheimer, Mindray Medical Int'l (NYSE: MR) Outperform rating is maintained.

Oppenheimer said that it sees resilience in China's medical device industry and little correlation of ShenZhen medical device exports with China's total exports. “We believe besides top-line growth, margins and 2012 guidance will be key factors affecting near-term stock price. Maintain Outperform.”

Mindray Medical Int'l closed yesterday at $25.48.

Posted-In: OppenheimerAnalyst Color Analyst Ratings


Related Articles (MR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→